Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes.
about
Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophreniaThe dopaminergic response in multiple system atrophy.Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's diseaseIdazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's diseaseNormal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopaEffects of acute memantine administration on MATRICS Consensus Cognitive Battery performance in psychosis: Testing an experimental medicine strategyAre we studying and treating schizophrenia correctly?Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease.Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group.Loss of olfaction in de novo and treated Parkinson's disease: possible implications for early diagnosis.Square wave jerks in parkinsonian syndromes.The apomorphine test in parkinsonian syndromesThe effects of acute levodopa withdrawal on motor performance and dopaminergic receptor sensitivity in patients with Parkinson's diseaseHMPAO SPECT in Parkinson's disease before and after levodopa: correlation with dopaminergic responsiveness.Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease.Extrapyramidalism in Alzheimer's disease: prevalence, psychiatric, and neuropsychological correlatesPen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study.Catatonia in depression: prevalence, clinical correlates, and validation of a scale.Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.Subcutaneous apomorphine increases regional cerebral blood flow in parkinsonian patients via peripheral mechanisms.Apomorphine in idiopathic restless legs syndrome: an exploratory study.Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up.Multiple system atrophy presenting as parkinsonism: clinical features and diagnostic criteria[123I]FP-CIT (DaTscan) SPECT brain imaging in patients with suspected parkinsonian syndromes.Role of apomorphine in the treatment of Parkinson's disease.Tachykinins, neurotrophism and neurodegenerative diseases: a critical review on the possible role of tachykinins in the aetiology of CNS diseases.Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.Apomorphine-induced penile erections in Parkinson's disease.Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease.Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan.Rigidity decreases resting tremor intensity in Parkinson's disease: A [(123)I]beta-CIT SPECT study in early, nonmedicated patients.Paradoxical response to apomorphine in a case of atypical parkinsonism.Apolaustic apomorphine.Neurophysiological biomarkers informing the clinical neuroscience of schizophrenia: mismatch negativity and prepulse inhibition of startle.Pharmacological Insights into the Use of Apomorphine in Parkinson's Disease: Clinical Relevance.The treatment of Parkinson's disease in older people.Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
P2860
Q27014120-C8149F4E-2402-459B-A217-E1D331DC15D8Q28317869-3349988D-5003-42F8-8AE9-9D114564A8DEQ28317873-9BDE6FB3-9E4E-416D-B3A9-1E21E9275A7CQ28375639-FB5CBB1F-AF14-4345-83AE-D7DA48BD50B3Q28378268-4E034685-C0B1-4EE6-BC6A-F5417E780B1AQ30355399-65A62B0B-1696-46A1-A246-B783347C59FAQ30465313-BBE699F7-5B91-430A-B1FD-94AF23FA0719Q30942227-43A24BCD-4F9C-4280-8399-81C2AB63DA4BQ31388180-F408A1EA-E3D9-41F1-B625-52AB0F225A70Q32052296-8F88C739-3DC2-4914-BD56-AB111CE51703Q33589536-6E363E9F-9741-4BC5-BD9C-C1BFC4B87785Q33589892-428FA7D5-19E5-4784-AA8D-565D19835A87Q33591306-798F9135-1224-48B6-A5F9-BF8DB0002380Q33731224-80A693A3-3F47-4743-94E6-30B100C08190Q33731230-1FD16398-DBCA-4C4A-8DF0-5ECF50C2DE24Q33733438-E9236875-5113-4405-A277-A8A33408438BQ33734263-36BA54E4-3A38-4194-95A3-067681E50BECQ33735106-29A38F25-C98B-410B-8B55-33EF0B44373FQ33735320-51D55985-3244-4403-A754-C73AF71BBDF3Q34358384-5C7E2C0C-65D7-4FFE-9AEE-C6BCABF2F117Q35486302-D258AEBA-E6E3-4CE7-BC15-4F6231F6D71EQ36319026-D4140DB6-6415-44A0-A5F3-17EFA0E91C34Q36879516-60623064-6DF1-4FC8-864E-2D4F67E4B40BQ37853646-78A3891B-5C81-47C5-8A16-D6B3CAA4E457Q38353520-53C9DDA7-87B1-46F9-B10C-03CA6E0AED1BQ41209277-88CCA27E-E763-4799-AFE5-FBEC1E6F8D9EQ42164149-B27D6632-D9F8-4BD3-8ED6-BB2C641B949BQ42541986-9DD8F3F3-BD65-485C-8E74-D0DD94432733Q43570440-F647975F-F784-4BF6-B651-901F7AF36072Q43693346-52CC4C2D-C58F-4297-9570-00E04BB594CDQ43827118-4A1830D9-EA57-496C-AAEB-85E4AF462A07Q44060173-1BBA1B26-A16F-47B7-B81A-1359C436E3E7Q45286267-35E0F6C2-C431-486E-AB50-B30DEE9E69A4Q46116077-FFBE2CE5-F2A7-4D32-9A35-B3785C5270FEQ47868277-791C8D5C-BFD8-4042-85F1-D28C2BC6CAADQ48338523-4D893AA8-A8D4-4C40-9680-82AA88960E72Q48494045-DFE9C9CE-4588-49A8-9649-B8F09FE45F1D
P2860
Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 1990
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes.
@en
Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes.
@nl
type
label
Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes.
@en
Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes.
@nl
prefLabel
Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes.
@en
Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes.
@nl
P1433
P1476
Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes.
@en
P2093
P356
10.1016/0140-6736(90)91531-E
P407
P577
1990-07-01T00:00:00Z